Cargando…

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadliest cancer worldwide. The primary reasons for this are the lack of early detection methods and targeted therapy. Emerging evidence highlights the metabolic addiction of cancer cells as a potential target to combat PDAC....

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yu-Huei, Hu, Chun-Mei, Hsu, Yuan-Sheng, Lee, Wen-Hwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508091/ https://www.ncbi.nlm.nih.gov/pubmed/36151074 http://dx.doi.org/10.1038/s41419-022-05259-w

Ejemplares similares

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma
por: Liu, Zhao, et al.
Publicado: (2023)

KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence
por: Amintas, Samuel, et al.
Publicado: (2022)

Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features
por: PENG, JIE, et al.
Publicado: (2013)

Notch1 Is Not Required for Acinar-to-Ductal Metaplasia in a Model of Kras-Induced Pancreatic Ductal Adenocarcinoma
por: Avila, Jacqueline L., et al.
Publicado: (2012)

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
por: Luchini, Claudio, et al.
Publicado: (2020)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma
por: Wang, Yuqiong, et al.
Publicado: (2021)

Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
por: Topham, James T., et al.
Publicado: (2022)

Metabolism remodeling in pancreatic ductal adenocarcinoma
por: Li, Jin-Tao, et al.
Publicado: (2019)

Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma
por: Zhu, Liang, et al.
Publicado: (2022)

PPDPF Promotes the Development of Mutant KRAS‐Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1
por: Ni, Qian‐Zhi, et al.
Publicado: (2022)

Role of PLEXIND1/TGFβ Signaling Axis in Pancreatic Ductal Adenocarcinoma Progression Correlates with the Mutational Status of KRAS
por: Vivekanandhan, Sneha, et al.
Publicado: (2021)

KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?
por: Shen, Henry, et al.
Publicado: (2022)

TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma
por: Zhou, Yiran, et al.
Publicado: (2023)

Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma
por: Ju, Huai-Qiang, et al.
Publicado: (2017)

Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer
por: Singh, Kanchan, et al.
Publicado: (2020)

KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas
por: Diehl, Adam C, et al.
Publicado: (2022)

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
por: Zhang, Joshua, et al.
Publicado: (2023)

Dual Inhibition of KRAS(G12D) and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
por: Gulay, Kevin Christian Montecillo, et al.
Publicado: (2023)

Oral mycobiota and pancreatic ductal adenocarcinoma
por: Wei, Ailin, et al.
Publicado: (2022)

Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma
por: Hafezi, Shirin, et al.
Publicado: (2021)

Correction to: Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer
por: Singh, Kanchan, et al.
Publicado: (2021)

Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma
por: Feigin, Michael E., et al.
Publicado: (2017)

The Role of Exosomes in Pancreatic Ductal Adenocarcinoma Progression and Their Potential as Biomarkers
por: Hsu, Sheng-Kai, et al.
Publicado: (2023)

Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma
por: Kong, Yao, et al.
Publicado: (2023)

Proteome alterations in pancreatic ductal adenocarcinoma
por: Pan, Sheng, et al.
Publicado: (2020)

Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma
por: Li, Junjie, et al.
Publicado: (2016)

Loss of Heterozygosity for Kras(G12D) Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF-2α-c-Myc-Regulated Glutamine Metabolism
por: Ma, Yu, et al.
Publicado: (2022)

Interplay Between Diabetes and Pancreatic Ductal Adenocarcinoma and Insulinoma: The Role of Aging, Genetic Factors, and Obesity
por: Duvillié, Bertrand, et al.
Publicado: (2020)

KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma
por: Park, Kyung Joo, et al.
Publicado: (2016)

Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report
por: Ardalan, Bach, et al.
Publicado: (2021)

Markers of Bone Metabolism in Patients With Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma
por: Pezzilli, Raffaele, et al.
Publicado: (2015)

Alterations in Glucose Metabolism Due to Decreased Expression of Heterogeneous Nuclear Ribonucleoprotein M in Pancreatic Ductal Adenocarcinoma
por: Takino, Jun-ichi, et al.
Publicado: (2021)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ufle47kqmm379a239qm5iln2p7